According to a recent LinkedIn post from Gallant, the company is promoting a live GallantU continuing education webinar focused on mesenchymal stromal cell therapy in animal health biotechnology. The session, led by Gallant’s Director of Veterinary Affairs, is RACE-approved and offers one continuing education credit for veterinarians.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Gallant is investing in clinician education around advanced regenerative therapies, which may help build brand recognition and credibility among veterinary professionals. This type of engagement could support longer-term demand for the company’s biotechnology offerings and reinforce its positioning in the emerging animal health stem cell and cell-therapy segment.